|
CURRENT NEWS
CNS Network selects ALPHADAS®, Logos Technologies Early Phase EDC System.
Read more
Spaulding Clinical's Innovations produce best quality in 240 Subject TQT Study.
Read more
Following Omnicomm Systems announcement in the press on 4th August 2009, Logos Holdings Ltd and Logos Technologies Inc were not affected by this and continue to own the Logos EDC assets and proprietary software known as ALPHADAS® as previously. The Logos group continue to be owned by the same shareholders.
For any enquiries relating to this announcement or ALPHADAS®, a world leading early phase EDC and Phase I site automation tool, please browse our website or
for further information.
‘Duke’s Phase I Trials Go Electronic’ – A report by Barry Mangum, Director of Clinical Pharmacology, Duke Clinical Research Unit, and Associate Clinical Professor of Clinical Pharmacology, Duke University Medical Center.
Read more
Qualia Clinical Services selects ALPHADAS® for Phase I Clinical Trials.
Read more
Logos wins Best IT Strategy at European Outsourcing Awards 2008.
Read more
Bio IT World - Duke goes with ALPHADAS® for its early phase trials.
Read more
Duke licenses ALPHADAS® Logos Technologies EDC software.
Read more
Three levels of integration for Exco Intouch, Logos Technologies, by Deborah Borfitz, eCliniqua.
Read more
OmniComm, Logos in EDC pact by Amy Swinderman, Drug Discovery News.
Read more
Exco InTouch Partners with Logos Technologies to Improve Patient Recruitment in Clinical Trials.
Read more
Omnicomm Systems Inc and Logos Technologies partner to provide superior Electronic Data Capture (EDC) for Phase I-IV clinical trials.
Read more
Comprehensive
NeuroScience /
Comprehensive
Phase One "Advanced technology to
benefit patients and sponsors..."
Read more
|